From the desk of Jeanne Hambleton
Members of the European Parliament (MEPs) adopt written declaration 69/2008 on fibromyalgia initiated by five deputies and the European Network of Fibromyalgia Associations (ENFA).
Brussels (16.12.2008) – Written Declaration 69/2008 on fibromyalgia has been a success in the European Parliament by finding the necessary quorum of signatories of 393 deputies giving their support. The Written Declaration was initiated by five key MEPs active on health at the European Parliament: Mr. Adamou, Ms. Brepoels, Ms. Dičkuté, Mr. Popa and Ms. Sinnott. These MEPs decided to launch the declaration during the celebratory meeting of the 1st European Fibromyalgia Awareness Day in May 2008, organized by ENFA
The Written Declaration is calling on the European Union to recognize fibromyalgia in Europe as a disease, as WHO did in 1992. It is estimated that 14 million people in Europe suffer from fibromyalgia and the condition is more prevalent with women (87% of total prevalence).
Fibromyalgia is a complex disease with a variety of symptoms in addition to the defining symptom – chronic widespread pain. These include fatigue, non-restorative sleep, morning stiffness, irritable bowel and bladder, restless legs, depression, anxiety and cognitive dysfunction often referred to as “fibro fog.” All of these symptoms cause serious limitations in patients’ ability to perform ordinary daily chores and work and severely affect their quality of life. Some scientists believe that there is an abnormality in how the body responds to pain, and particularly a heightened sensitivity to stimuli.
Fibromyalgia imposes large economic burdens on society as well as on affected individuals. A study shows that an average patient in Europe consults up to 7 physicians and takes multiple medications over 5-7 years before receiving the correct diagnosis. The debilitating symptoms often result in lost work days, lost income and disability payments. Research in the UK has shown that diagnosis and positive management of Fibromyalgia reduce healthcare cost by avoiding unnecessary investigations and consultations
Thus, the European Parliament is calling through this declaration, for the European Commission and the Council, to help raise awareness of the condition and facilitate access to information for health professionals and patients, by supporting European and national awareness campaigns; to encourage Member States to improve access to diagnosis and treatment; to facilitate research on fibromyalgia through the work programmes of the EU 7th Framework Programme for Research and future research programmes; and finally to facilitate the development of programmes for collecting data on fibromyalgia.
Educating healthcare professionals, patients and the public to promote better understanding and management of Fibromyalgia will benefit patients, healthcare providers and the society.
A Written Declaration is a text of up to 200 words on a matter falling within the European Union’s sphere of activities. MEPs can use them in order to launch or relaunch a debate on a subject that comes within the EU’s remit. At the end of the lapsing date (3 months after its launch on 1 September for the declaration 69/2008) the declaration is forwarded to the institutions named in the text, together with the names of the signatories.
European Network of Fibromyalgia Associations (ENFA)
Mr. Robert Boelhouwer
President of ENFA
ENFA is a network of patient association and support groups working in close consultation with the national association in the relevant country. Our joint missions are to conquer the myths and misunderstandings around Fibromyalgia. The network will help collectively push forward the boundaries which currently exist in understanding, experiencing and treatment of Fibromyalgia. Our main goal is to see fibromyalgia receiving the recognition it deserves across Europe as an illness in its own right.
Contact: Angela Babb
American Academy of Neurology
ST. PAUL, Minn. – People taking cholesterol-lowering drugs such as atorvastatin after a stroke may be at an increased risk of hemorrhagic stroke, or bleeding in the brain, a risk not found in patients taking statins who have never had a stroke. But researchers caution the risk must be balanced against the much larger overall benefit of the statin in reducing the total risk of a second stroke and other cardiovascular events when making treatment decisions. The research is published in the December 12, 2007, online issue of Neurology®, the medical journal of the American Academy of Neurology.
For the study, researchers conducted a secondary analysis of the results of the Stroke Prevention with Aggressive Reduction in Cholesterol Levels (SPARCL) clinical trial. The trial enrolled 4,731 people who were within one to six months of having had a stroke or transient ischemic attack, or mini-stroke, and with no history of heart disease. Half of the participants received atorvastatin and half received a placebo. The participants were then followed for an average of four and a half years.
Overall, treatment was associated with a 16-percent reduction in total stroke, the study’s primary endpoint, as well as significant reductions in coronary heart events. However, secondary analysis found that the overall reduction in stroke included an increase in the risk of brain hemorrhage. Of those people randomized to atorvastatin, the study found 2.3 percent experienced a hemorrhagic stroke during the study compared to 1.4 percent of those taking placebo. The study also found there was a 21-percent reduction in ischemic stroke, a more common type of stroke involving a block in the blood supply to the brain, among people taking atorvastatin.
Other factors were also found to increase the risk of brain hemorrhage. For example, those who had experienced a hemorrhagic stroke prior to the study were more than five times as likely to suffer a second stroke of this kind. Men were also nearly twice as likely as women to suffer a hemorrhagic stroke. People with severe high blood pressure at their last doctor’s visit prior to the hemorrhagic stroke had over six times the risk of those with normal blood pressure.
“Although treatment of patients with a stroke or transient ischemic attack was clearly associated with an overall reduction in a second stroke, hemorrhagic stroke was more frequent in people treated with atorvastatin, in those with a prior hemorrhagic stroke, in men and in those with uncontrolled hypertension,” according to study author Larry B. Goldstein, MD, with Duke University Medical Center in Durham, North Carolina, and Fellow of the American Academy of Neurology. “This risk of hemorrhagic stroke also increased with age.”
“Treatment with atorvastatin did not disproportionately increase the frequency of brain hemorrhage associated with these other factors. The risk of hemorrhage in patients who have had a transient ischemic attack or stroke must be balanced against the benefits of cholesterol-lowering drugs in reducing the overall risk of a second stroke, as well as other cardiovascular events,” said Goldstein.
The SPARCL trial was funded by Pfizer, the maker of atorvastatin.
The American Academy of Neurology, an association of more than 20,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as stroke, Alzheimer’s disease, epilepsy, Parkinson disease, and multiple sclerosis.
For more information about the American Academy of Neurology, visit http://www.aan.com.
Contact: Beth Bukata
American Society for Therapeutic Radiology and Oncology
Internet resources and access remain scarce
Although Spanish-speaking cancer patients are rapidly increasing their search for patient education resources on the Internet, there are very few Spanish-language Web sites available to provide this information, according to a study presented October 28, 2007, at the American Society for Therapeutic Radiology and Oncology’s 49th Annual Meeting in Los Angeles.
Spanish-speaking cancer patients were also shown to have more limited access to the Internet compared to English-speaking users of cancer information Web sites, based on the user patterns of the two groups.
“There is an urgent need for more Web-based information to be more available to Spanish-speaking patients with cancer, and Internet access needs to be more widely available,” said Charles Simone II, M.D., lead author of the study and a radiation oncologist at the Hospital of the University of Pennsylvania in Philadelphia. “The increased knowledge gained among these patients will help to eliminate healthcare disparities and lead to improved medical outcomes.”
The Spanish-language cancer information Web site, OncoLink en español, quadrupled their number of unique visitors last year, from 7,000 visitors per month in January 2006 to nearly 29,000 monthly visitors by the end of the year. More than 200,000 users visited the Web site in 2006.
In contrast, the English-language version of the site, OncoLink, had nearly 2 million visitors last year, although their number of unique visitors did not increase throughout the year. OncoLink en espanõl was launched in 2005 by OncoLink, one of the oldest and largest Internet-based cancer information resources. Both sites are managed by the University of Pennsylvania.
The study shows that OncoLink en español users were less likely to browse the Internet during weekends and morning hours, compared to the users who browsed OncoLink, suggesting that they are accessing the Internet more through work or specialized services.
In addition to when they accessed the Internet, OncoLink en español users also differed on the types of cancers they searched for, as well as the timing and method of their Internet search patterns.
“Awareness of these differences can assist cancer education Web sites to tailor their content to best meet the needs of their Spanish-speaking users,” said Dr. Simone.
The study was carried out using AWStats, a Web-data analyzing program, to collect and compare statistical data from the secure servers of both language versions of OncoLink.
For more information on radiation therapy in English and in Spanish, visit http://www.rtanswers.org.
The abstract, “The Utilization of Radiation Oncology Web-based Resources in Spanish-speaking Oncology Patients,” will be presented for poster viewing starting at 10:00 a.m, Sunday, October 28, 2007. To speak to the study author, Charles Simone, II, M.D, please call Beth Bukata or Nicole Napoli October 28-31, 2007, in the ASTRO Press Room at the Los Angeles Convention Center at 213-743-6222 or 213-743-6223. You may also e-mail them at firstname.lastname@example.org or email@example.com.
Global Fibromyalgia Syndrome (FMS) and Chronic Fatigue Syndrome (CFS) News.
Fibromyalgia syndrome : New developments in pharmacotherapy.
Schwerpunkt Rheumatologie, Sophienblatt 1, 24103, Kiel, Deutschland, firstname.lastname@example.org.
Fibromyalgia syndrome (FMS) affects 2-10% of the adult population in industrial countries and although it is associated with substantial morbidity and disability, treatment options are unsatisfactory. The rapid growth of trials for FMS in recent years has resulted in new, evidence-based approaches to medical treatment. This review focuses on the randomized, controlled studies of newer pharmacological options for FMS, such as selective serotonin/norepinephrine reuptake inhibitors (duloxetine, milnacipran), inhibitors of voltage-gated calcium channels (pregabalin, gabapentin), dopamine-2/3-receptor agonists (pramipexole, ropirinole), sedative-hypnotic agents (sodium oxybate, modafinil, dronabinol), 5-HT3 antagonists (tropisetron) and others (tramadol, dextromethorphan, olanzapine).
Contact: Yivsam Azgad
Weizmann Institute of Science
A group of Israeli scientists from the Technion – Israel Institute of Technology, the Weizmann Institute of Science and Teva Pharmaceutical Industries have recently identified genes responsible for the positive response of many multiple sclerosis patients to the drug Copaxone®. These findings may contribute to the development of personalized medicine for multiple sclerosis sufferers.
Copaxone® was the first original Israeli drug to be approved by the U.S. Food and Drug Administration (FDA), and is today marketed in over 40 countries worldwide, including the U.S.A., Europe, Australia, Latin America and Israel.
The drug molecule was the fruit of research by Prof. Michael Sela, Prof. Ruth Arnon and Dr. Dvora Teitelbaum of the Weizmann Institute’s Immunology Department. It was developed for the treatment of multiple sclerosis (MS) by Teva, which produces and markets Copaxone® today.
‘Until now, medical treatments for all kinds of diseases have relied on trial and error methods to determine dosage and treatment protocols,’ says Prof. Ariel Miller of the Ruth and Bruce Rappaport Faculty of Medicine at the Technion, and Head of the Multiple Sclerosis and Brain Research Center, Carmel Medical Center, Haifa. ‘But the process of fixing the correct dosage affects the efficacy of the treatment and can lead to complications in some cases.’ In the past few years, it has been shown that many drugs are not equally effective for every patient, and this variability is due, at least in part, to genetic differences. Finding medications and doses to suit the genetic make-up of each individual patient is likely to be more successful and to cause fewer side effects.
The new research, which deals with the genetic components of the response to Copaxone®, was recently published in the journal Pharmacogenetics and Genomics. It represents a significant step toward realizing this medical vision. In the collaborative study, Teva supplied DNA samples from drug-treated patients, and the genetic tests were performed at the Crown Human Genome Center of the Weizmann Institute, headed by Prof. Doron Lancet of the Institute’s Department of Molecular Genetics. The scientists used state-of-the-art equipment – the first of its kind in Israel –which allows for the rapid and accurate scanning of variations in the human genome. The scientists then examined the links between the genetic markers they found and the response of MS patients to Copaxone®. They identified several genes that are tied to a positive response to the drug. ‘We analyzed the DNA sequences in 27 candidate genes from each patient participating in the trial,’ said Lancet, ‘and we identified two genes with a high potential for determining the response to Copaxone®. In the future, it may be possible to use this method to scan the genome of MS sufferers, to predict the response levels in advance, and to optimize the dosage and treatment protocol to suit each patient personally.’
Also participating in the research were Prof. Jacques Beckmann (formerly at the Weizmann Institute); Drs. Liat Hayardeny and Dan Goldstaub of Teva; and Iris Grossman, a joint research student at the Technion and the Weizmann Institute.
Copaxone® – Interface between Past and Future
In the 1950’s, Prof. Efraim Katzir of the Weizmann Institute of Science, later fourth president of the State of Israel, commenced research on the properties of proteins – the building blocks of all biological systems. This research led to the design of simple synthetic models of proteins, called ‘polyamino acids.’ His research student at the time, Prof. Michael Sela (who later became President of the Weizmann Institute and was the recipient of, among many honors, the Israel Prize), decided to test the influence of these synthetic molecules on the immune system. This research led him to the conclusion that it might be possible to use these synthetic substances to curb symptoms of multiple sclerosis – an autoimmune disease in which the body’s immune system attacks proteins in the fatty layer surrounding nerve fibers, preventing the conductance of electrical signals through them. Sela, together with his student at the time, Prof. Ruth Arnon (recipient of the Israel Prize and past Vice President of the Weizmann Institute and Vice President of the Association of Academies of Sciences in Asia), and Dr. Dvora Teitelbaum, conducted a long series of experiments. These experiments eventually led to the development of Copaxone®, and clinical trials carried out by Teva showed its efficacy in treating MS. At the end of the process, in 1996, Copaxone® became the first original Israeli drug to be approved by the FDA. Today, following ten years of active sales in the U.S. and 40 countries around the world, Copaxone® has made a significant contribution to the Israeli economy.
Prof. Doron Lancet’s research is supported by the Nella and Leon Benoziyo Center for Neurological Diseases; the Crown Human Genome Center; and the Laub Fund for Oncogene Research. Prof. Lancet is the incumbent of the Ralph and Lois Silver Professorial Chair in Human Genomics.
The Weizmann Institute of Science in Rehovot, Israel, is one of the world’s top-ranking multidisciplinary research institutions. Noted for its wide-ranging exploration of the natural and exact sciences, the Institute is home to 2,600 scientists, students, technicians and supporting staff. Institute research efforts include the search for new ways of fighting disease and hunger, examining leading questions in mathematics and computer science, probing the physics of matter and the universe, creating novel materials and developing new strategies for protecting the environment.
Weizmann Institute news releases are posted on the World Wide Web at http://wis-wander.weizmann.ac.il.
- 25-hydroxyvitamin D
- Acetaminophen and Caffeine
- Acinetobacter calcoaceticus-baumannii complex
- acute lymphoblastic leukemia
- American Academy of Neurology
- American Association for Cancer Research
- American Chemical Society
- American College of Cardiology
- American Heart Association
- American Journal of Clinical Nutrition
- American Journal of Public Health
- American Legacy Foundation
- Ancestral Heritage
- Archives of Neurology
- Arthritis & Rheumatism
- Autism Spectrum Disorders
- Autoimmune Diseases
- B. Rappaport Faculty of Medicine at Technion in Haifa
- Biological Sciences
- Blackwell Publishing Ltd.
- Bone Demineralisation
- Bone Diseases
- British Medical Journal
- Brooke Army Medical Center
- Buck Institute
- Calabria Regional Health Department
- Canadian Institutes of Health Research
- Cancer Biology
- Cancer Biology and Therapy
- Cancer Information In Spanish
- Cardiovascular Disease
- Catalan Institute of Oncology in Spain
- Childhood Lukemia
- Childhood Nutrition
- Children's Hospital of Philadelphia
- Children’s Cancer Institute Australia
- Children’s Hospital
- Children’s Hospital of Philadelphia
- Childrens Hospital Los Angeles
- Chromosome 17
- Chromosome 8
- Chronic Multisymptom Illnesses
- Chronic Stress
- Chronic Stress and Obesity
- CHS National Cancer Control Center and Technion
- CHS National Israeli Cancer Control Center
- Clinical Applications
- Clinical Trials
- College of Medicine in Houston
- Complex Chronic Conditions
- Cornell University
- Cytochrome b5
- Cytochrome P450
- Drug Abuse
- Duke University Medical Center
- Electronic Health Records
- Emergency Preparedness
- Emergency Room
- Emory Genetics Laboratory
- Emory University
- End Of Life Care
- European Cancer Conference
- European Journal of Cancer Care
- European League Against Rheumatism
- European Science Foundation
- FDA Warnings
- Fibromyalgia News
- FMS Global News
- Folic Acid
- Fort Sam Houston
- Fox Chase Cancer Center
- Fred Hutchinson Cancer Research Center
- Garvan Institute of Medical Research
- General Psychiatry
- Genetic Link
- Genetic Marker C allele of rs10505477
- Global Health Vision
- Global News
- Health Canada
- Health Information Technology
- Heart Disease
- Hebrew University of Jerusalem
- Hemorrhagic Stroke
- Historical Medicine
- Hospital Epidemiology
- Hospital Trauma
- Howard Hughes Medical Institute
- Human Genome
- Huntington's disease
- Imperial College London
- Interactive Autism Network
- Inuit children
- Irving Weinstein Foundation
- JAMA/Archives journals
- Japanese Society for the Promotion of Science
- Johns Hopkins University
- Joint Health Research Program
- journal BBA Biomembranes
- journal Cell
- journal Nature Genetics
- Journal of Clinical Investigation
- Journal of Experimental Social Psychology
- Journal of the American College of Surgeons
- Journal of Theoretical Biology
- Juvenile Diabetes
- Karolinska Institute in Stockholm
- Kennedy Krieger Institute
- Kyowakai Hospital
- Lamezia Terme
- London UK Feed
- Lung Cancer
- Massachusetts General Hospital
- Mayo Clinic
- McMaster University
- Medical History
- Medical Insurance
- Medical Journals
- Mitochondrial Diseases
- Molecular Biology
- Molecular Epidemiology
- Multiple Sclerosis
- Muscular Dystrophy
- Music Video Of The Day
- Music Video Pick Of The Day
- National Cancer Institute
- National Institute on Aging
- National Institutes of Health
- Nature Genetics
- Neurodegenerative Diseases
- Neuropeptide Y
- New England Journal of Medicine
- New York University
- News Australia
- News Canada
- News France
- News Germany
- News Israel
- News Italy
- News Jerusalem
- News Switzerland
- News UK
- News US
- News USA
- non-Hodgkin's lymphoma
- Northwestern University
- Nova Scotia
- Nutritional Anthropology
- Oak Ridge National Laboratory
- Occupational Health
- omega-3 fatty acids
- Orthopaedic Research Society
- Ottawa City Feed
- Oxford University
- Pain Management
- Palliative Care
- Parkinson Society of Canada
- Pediatric Palliative Care
- Peutz-Jeghers syndrome
- Pharmacology and Neuroscience
- Pick's Disease
- Pre/Post Natal Care
- Preventive Medicine
- Prince Edward Island
- Protein Growth Factor
- Public Health
- Research Australia
- Rheumatoid Arthritis
- RSS Feed
- Rush Alzheimer’s Disease Center
- Seattle Washington
- Spina Bifida
- Spinal Cord Injuries
- St. Elmos Fire
- St. Jude Children's Research Hospital
- Statin Drugs
- Stem Cells
- Sydney Children’s Hospital
- Systemic Lupus Erythematosus
- Temple University
- The American Academy of Neurology
- the Israel Institute of Technology
- Toronto City Feed
- trauma-associated and hospital-acquired infection
- Type 1 Diabetes
- Type 2 Diabetes
- Université Laval
- University College London
- University Hospital in Geneva
- University New South Wales
- University of Bern
- University of Calgary
- University of California
- University of Chicago
- University of Chicago Press Journals
- University of Florida
- University of Granada
- University of Manchester
- University of Michigan
- University of Missouri
- University of North Carolina
- University of North Texas
- University of Nottingham
- University of Oregon
- University of Pennsylvania School of Medicine
- University of Pittsburgh
- University of Rochester
- University of Toronto
- US Army soldiers in Iraq
- US Military Hospitals
- UT Southwestern Medical Center
- Vitamin D
- W. Garfield Weston Fellows
- Wake Forest University Baptist Medical Center
- Washington DC
- Washington DC City Feed
- Washington University
- Weather Anomolies
- Weill Medical College
- Wellcome Trust
- World Health Organisation
- World News
- Yale University